Moderna Finalizes Enrollment for Phase 3 COVID-19 Vaccine Trial
Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273.
The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.
The primary endpoint is prevention of coronavirus symptoms, with secondary endpoints including prevention of infection and severe disease.
Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine won’t be available for widespread distribution until Spring 2021, most likely late in the first quarter or early in the second quarter.